Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q1664196> ?p ?o }
Showing triples 1 to 53 of
53
with 100 triples per page.
- Q1664196 subject Q7028909.
- Q1664196 subject Q7031265.
- Q1664196 subject Q7056690.
- Q1664196 abstract "The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.The funding scheme has been criticised, requiring universities to invest more money than with EU FP7 programs. Besides the non-competitive financial aspects of participation in IMI projects for academia, this criticism also discusses that intellectual property is freely flowing to industry.The Sixth Framework Programme's research projects InnoMed AddNeuroMed and InnoMed PredTox acted as pilot projects establishing the feasibility of this particular public-private partnership. Since then, the IMI has had four funding rounds: the first call had the topic Safety, while the second call was about Efficacy. Projects for these two calls are ongoing.The IMI 2 started in 2014 and will run until 2024, while the IMI 1 is still running. Overall budget is €3.276 billion, taken for half from the European Horizon 2020 program. Goals of that second calls are to improve clinical trials success rate, deliver clinical proof of concept, biomarkers and new medicines.".
- Q1664196 fundedBy Q1376562.
- Q1664196 fundedBy Q8880.
- Q1664196 projectBudgetFunding "1.0E9".
- Q1664196 projectBudgetTotal "2.0E9".
- Q1664196 projectKeyword "Drug discovery,Drug development".
- Q1664196 projectObjective "Re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development (R&D) investment in this sector".
- Q1664196 projectType "Joint Technology Initiative(JTI)".
- Q1664196 title "Joint Technology Initiative on Innovative Medicines".
- Q1664196 wikiPageExternalLink www.imi.europa.eu.
- Q1664196 wikiPageExternalLink www.imi.europa.eu.
- Q1664196 wikiPageWikiLink Q1376562.
- Q1664196 wikiPageWikiLink Q1418791.
- Q1664196 wikiPageWikiLink Q1438124.
- Q1664196 wikiPageWikiLink Q177773.
- Q1664196 wikiPageWikiLink Q18210350.
- Q1664196 wikiPageWikiLink Q20090789.
- Q1664196 wikiPageWikiLink Q2198549.
- Q1664196 wikiPageWikiLink Q221096.
- Q1664196 wikiPageWikiLink Q3304308.
- Q1664196 wikiPageWikiLink Q458.
- Q1664196 wikiPageWikiLink Q54129.
- Q1664196 wikiPageWikiLink Q5507125.
- Q1664196 wikiPageWikiLink Q7028909.
- Q1664196 wikiPageWikiLink Q7031265.
- Q1664196 wikiPageWikiLink Q7056690.
- Q1664196 wikiPageWikiLink Q7180763.
- Q1664196 wikiPageWikiLink Q8880.
- Q1664196 budget "2.0E9".
- Q1664196 funding "1.0E9".
- Q1664196 fundingagency Q8880.
- Q1664196 fundingagency "European Federation of Pharmaceutical Industries and Associations".
- Q1664196 keywords Q1418791.
- Q1664196 keywords Q2198549.
- Q1664196 name "Innovative Medicines Initiative".
- Q1664196 projecttype Q5507125.
- Q1664196 researchobjective "Re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development investment in this sector".
- Q1664196 title "Joint Technology Initiative on Innovative Medicines".
- Q1664196 website www.imi.europa.eu.
- Q1664196 type Project.
- Q1664196 type ResearchProject.
- Q1664196 type UnitOfWork.
- Q1664196 type PlanExecution.
- Q1664196 type Situation.
- Q1664196 type Thing.
- Q1664196 type Q1298668.
- Q1664196 comment "The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme.".
- Q1664196 label "Innovative Medicines Initiative".
- Q1664196 homepage www.imi.europa.eu.
- Q1664196 name "Innovative Medicines Initiative".